Yuki Enoki Selected Research

Pharmaceutical Preparations

12/2021	Long-term pharmaceutical stability of liposome-encapsulated methemoglobin as an antidote for cyanide poisoning.
11/2021	Cefmetazole as an Alternative to Carbapenems Against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Infections Based on In Vitro and In Vivo Pharmacokinetics/Pharmacodynamics Experiments.
10/2021	Liposome-encapsulated methemoglobin as an antidote against cyanide poisoning.
7/2021	Species Distribution of Candidemia and Their Susceptibility in a Single Japanese University Hospital: Prior Micafungin Use Affects the Appearance of Candida parapsilosis and Elevation of Micafungin MICs in Non-parapsilosis Candida Species.
1/2021	Pharmacokinetics/Pharmacodynamics Evaluation of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli In Vitro and In Vivo in a Murine Thigh Infection Model.
11/2020	Azoles versus conventional amphotericin B for the treatment of candidemia: A meta-analysis of randomized controlled trials.
11/2020	Echinocandins versus non-echinocandins for the treatment of invasive candidiasis: A meta-analysis of randomized controlled trials.
12/2019	Experimental verification of factors influencing calcium salt formation based on a survey of the development of ceftriaxone-induced gallstone-related disorder.
12/2017	Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuki Enoki Research Topics

Disease

8	Infections 03/2022 - 01/2014
6	Neoplasms (Cancer) 01/2022 - 05/2019
5	Chronic Renal Insufficiency 01/2022 - 01/2016
3	Poisoning 01/2022 - 10/2021
3	Acute Kidney Injury (Acute Renal Failure) 12/2021 - 01/2019
3	Sarcopenia 12/2021 - 01/2016
3	Muscular Atrophy (Muscle Atrophy) 12/2021 - 01/2016
2	Bacterial Meningitis 08/2022 - 09/2021
2	Meningitis 08/2022 - 09/2021
2	Pneumonia (Pneumonitis) 01/2022 - 01/2021
2	Rhabdomyolysis 01/2022 - 01/2020
2	Mitochondrial Diseases (Mitochondrial Disease) 12/2021 - 10/2017
2	Invasive Candidiasis 11/2021 - 11/2020
2	Clostridium Infections 10/2021 - 11/2018
2	Candidemia 07/2021 - 11/2020
2	Secondary Hyperparathyroidism 12/2017 - 01/2017
2	Atrophy 10/2017 - 01/2016
2	Human Influenza (Influenza) 01/2015 - 01/2014
2	Virus Diseases (Viral Diseases) 01/2015 - 01/2014
2	Lung Injury 01/2015 - 01/2014
1	Bacteremia 03/2022
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Bronchiolitis 01/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022
1	Acidosis 01/2022
1	Hematologic Neoplasms (Hematological Malignancy) 11/2021
1	Body Weight (Weight, Body) 11/2021
1	Escherichia coli Infections 11/2021
1	Hypoalbuminemia 06/2021

Drug/Important Bio-Agent (IBA)

9	Pharmaceutical PreparationsIBA 12/2021 - 12/2017
4	Anti-Bacterial Agents (Antibiotics)IBA 08/2022 - 01/2015
4	Proteins (Proteins, Gene)FDA Link 08/2022 - 01/2014
4	Vancomycin FDA LinkGeneric 03/2022 - 11/2018
4	EchinocandinsIBA 07/2021 - 06/2020
4	IndicanIBA 01/2020 - 01/2016
3	Daptomycin FDA Link 03/2022 - 06/2021
3	Carbon MonoxideIBA 01/2022 - 01/2020
3	AntidotesIBA 01/2022 - 10/2021
3	MethemoglobinIBA 01/2022 - 10/2021
3	Cyanides (Isocyanides)IBA 01/2022 - 10/2021
3	Uremic ToxinsIBA 01/2020 - 01/2016
3	MyostatinIBA 01/2019 - 01/2016
2	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 08/2022 - 12/2019
2	Linezolid (Zyvox)FDA Link 01/2022 - 09/2021
2	Cytochrome P-450 CYP3AIBA 01/2022 - 12/2017
2	Therapeutic UsesIBA 01/2022 - 01/2022
2	Electron Transport Complex IV (Cytochrome c Oxidase)IBA 01/2022 - 10/2021
2	salicylhydroxamic acid (SHAM)IBA 01/2022 - 10/2017
2	Liposomes (Liposome)IBA 12/2021 - 10/2021
2	NADPH Oxidases (NAD(P)H oxidase)IBA 12/2021 - 01/2020
2	beta-Lactamases (beta-Lactamase)IBA 11/2021 - 01/2021
2	Metronidazole (Metric)FDA LinkGeneric 10/2021 - 11/2018
2	A-factor (Streptomyces)IBA 10/2021 - 12/2019
2	Cystatin CIBA 06/2021 - 01/2021
2	PolyenesIBA 11/2020 - 11/2020
2	Sulfates (Sulfates, Inorganic)IBA 01/2020 - 02/2015
2	AST 120IBA 01/2020 - 10/2017
2	Parathyroid Hormone (Parathormone)IBA 12/2017 - 01/2017
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2015 - 01/2014
2	Hydroxyl RadicalIBA 01/2015 - 01/2014
1	Ceftazidime (Fortum)FDA LinkGeneric 08/2022
1	Adenosine Monophosphate (AMP)IBA 03/2022
1	Interleukin-17 (Interleukin 17)IBA 01/2022
1	Gemcitabine FDA Link 01/2022
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022
1	NivolumabIBA 01/2022
1	Blood Substitutes (Artificial Blood)IBA 01/2022
1	Clarithromycin (Biaxin)FDA LinkGeneric 01/2022
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2022
1	CytidineIBA 01/2022
1	AcidsIBA 01/2022
1	Ethambutol (Myambutol)FDA LinkGeneric 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	tedizolidIBA 01/2022
1	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 01/2022
1	Rifampin (Rifampicin)FDA LinkGeneric 01/2022
1	2-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA 01/2022
1	ProdrugsIBA 01/2022
1	Phenobarbital (Luminal)FDA Link 01/2022
1	Cisplatin (Platino)FDA LinkGeneric 12/2021
1	Hemoglobins (Hemoglobin)IBA 12/2021
1	SuspensionsIBA 12/2021
1	Advanced Oxidation Protein Products (AOPP)IBA 12/2021
1	AlbuminsIBA 12/2021
1	CreatinineIBA 11/2021
1	Fluconazole (Zonal)FDA LinkGeneric 11/2021
1	Cefmetazole (Cefmetazole Sodium)FDA Link 11/2021
1	Carbapenems (Carbapenem Antibiotics)IBA 11/2021
1	Nitrous Acid (Acid, Nitrous)IBA 10/2021
1	Hydroxocobalamin FDA Link 10/2021
1	Antifungal AgentsIBA 07/2021
1	Micafungin (FK463)FDA Link 07/2021
1	AntibodiesIBA 01/2021
1	Programmed Cell Death 1 ReceptorIBA 01/2021
1	TeicoplaninIBA 01/2021
1	remdesivirIBA 01/2021

Therapy/Procedure

6	Therapeutics 01/2022 - 11/2018
1	Lung Transplantation 01/2022
1	Aftercare (After-Treatment) 01/2022